User Tools

Site Tools


cardio:beta_blockers:bisoprolol

This is an old revision of the document!


Bisoprolol

Bisoprolol is a 2nd-generation, highly β1-selective beta-blocker.

It reduces heart rate, contractility, and renin release with minimal β2 activity at therapeutic doses.

Classification: • 2nd Generation (Cardioselective) • No intrinsic sympathomimetic activity (ISA)

Beta-Blockers Overview


Mechanism of Action

Selective β1 blockade:

• ↓ Heart rate • ↓ Contractility • ↓ AV nodal conduction • ↓ Renin release

Net Effects:

• ↓ Cardiac output • ↓ Blood pressure • ↓ Myocardial oxygen demand

High β1 selectivity makes it safer in patients with reactive airway disease compared to nonselective agents.

Selectivity is dose-dependent.


Indications

Heart Failure (HFrEF) ★

• Proven mortality benefit • Reduces hospitalizations • Part of guideline-directed medical therapy (GDMT)

Heart Failure Module

Evidence-based HFrEF beta-blockers:

CarvedilolMetoprolol Succinate • ★ Bisoprolol


Hypertension

• Effective antihypertensive • Not first-line for uncomplicated HTN

Hypertension Module


Coronary Artery Disease

• Reduces myocardial oxygen demand • Used post-MI


Arrhythmias

• Rate control in atrial fibrillation • Suppress supraventricular tachycardia

Dysrhythmias Module


Dosing in HFrEF

• Start low • Titrate slowly every 2–4 weeks • Initiate only when patient is euvolemic • Avoid starting during acute decompensation


Adverse Effects

• Bradycardia • Hypotension • Fatigue • Dizziness • Masked hypoglycemia

Lower bronchospasm risk than nonselective agents.


Contraindications

• Severe bradycardia • High-grade AV block (without pacemaker) • Cardiogenic shock • Acute decompensated heart failure

Use caution in: • Asthma (though safer than nonselective agents) • Severe hypotension


Bisoprolol vs Other HF Beta-Blockers

Carvedilol: • α1 + β blockade • More vasodilation • More orthostatic hypotension

Metoprolol Succinate: • β1 selective • Extended-release

Bisoprolol: • Highly β1 selective • Once-daily dosing • Strong mortality data

All three reduce mortality in HFrEF.


Clinical Pearls

✔ One of three mortality-reducing beta-blockers in HFrEF ✔ Highly β1 selective ✔ Once-daily dosing ✔ Safer in mild reactive airway disease ✔ Not first-line for uncomplicated hypertension


Related:

Beta-Blockers OverviewHeart Failure ModuleHypertension ModuleDysrhythmias ModuleReturn to Cardiovascular Modules

cardio/beta_blockers/bisoprolol.1770939387.txt.gz · Last modified: by andrew2393cns